Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives

ACW presents at Sachs Neuroscience Forum & WHO grants 'emestedastat' INN for Xanamem

ACW’s CEO Dr Steven Gourlay and senior executives  are in San Francisco and will present at the Sachs Annual Neuroscience Innovation Forum and participate in a significant number of  meetings associated with the  Annual J.P. Morgan Healthcare Conference week.

The company also announced that the World Health Organization has granted the nonproprietary name ‘emestedastat’ for Xanamem. An INN is a unique, globally recognized name for a pharmaceutical drug or active ingredient.

Daily Mail Online article on Actinogen and Xanamem

A great start to the New Year with an article appearing in the Daily Mail Online News section about the exciting propsects for Xanamem in the treatment of Alzheimer’s disease.

ACW to list 5 cent options expiring 31 May 2027

ACW announces that it intends to list its 5 cent unlisted options expiring 31 May 2027 that were issued in relation to its capital raising in May 2024. The options will have ASX security code ACWOD.

It is expected that the options will begin trading on Tuesday 17 December 2024.

ACW first US patient randomized in our XanaMIA Ph2b/3 trial for AD

Big milestone! ACW is excited to announce the first US patient randomized in our XanaMIA Ph2b/3 trial for AD.